Skip to main content

Table 3 Deterministic & probabilistic results for ranolazine plus SoC vs SoC alone

From: Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study

  Deterministic results Probabilistic results
Costs Ranolazine SoC Incremental Ranolazine SoC Incremental
Mean (95 % CI)
Total Costs (€) 1170 984 186 1170 (1123; 1213) 985 (933; 1036) 184 (154; 216)
Health outcomes     
QALYs 0.3155 0.2752 0.0403 0.3157 (0.3093; 0.3221) 0.2754 (0.2672; 0.2836) 0.0402 (0.0345; 0.0456)
Incremental analysis     
ICER per QALY (€)   4620   4904 (3526; 5962)
  1. ICER: incremental cost effectiveness ratio, QALY: quality-adjusted life year, SoC: standard of care, CI: confidence interval